Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Refractory Distant Metastatic Cutaneous Melanoma
NCT02581930Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in cutaneous melanoma (CM), sponsored by National Cancer Institute. Started Dec 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT02581930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581930.